The “Tech” Behind Biotechnology Has Evolved; 2015 Marks New Milestones

CORAL GABLES, FL / ACCESSWIRE / May 7, 2015 / The biotechnology industry has come a long way from where it was even 10 years ago. New findings, developments, and enacted regulations have given rise to programs only once dreamed of. Nearly half of America is behind the legalization of cannabis; many in favor of medical use and other novel therapies to treat the effects of cancer. Companies like Oxis International, Inc. (OTCQB: OXIS), PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), and PharmaCyte Biotech, Inc. (OTCQB: PMCB) have all begun the push for brining certain therapies to market.

Oxis International (OTCQB: OXIS) develops, commercializes, and addresses existing clinical shortcomings of related products with innovative drugs containing therapeutic molecules such as cannabinoids, which are focused on several cancer indicators. The Company looks to produce a platform of synthesized cannabinoid agents that target the treatment of cancer cells in multiple areas. Over the last 5 months the stock has moved from prices in December of $0.0131 to recent highs of $0.07. Currently the stock has traded between $0.0291 and $0.0344 since the beginning of the month.

Last month Oxis CEO Tony Cataldo accepted an invitation to participate in the Business of Biotech 2015 conference on April 17 at the Moffitt Cancer Center in Tampa, Florida. Mr. Cataldo stated, “Oxis is now in a position to make a major move forward with its high value technologies which are at the leading edge of immunotherapeutics in the very large cancer therapies markets.” 

PharmaCyte Biotech (OTCQB: PMCB) has a different approach to cell therapeutics. PharmaCyte is a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R). Recently the Company has been focusing on its diabetes therapies and has completed the construction of its International Diabetes Consoritum. This is made up of a global coalition of world class experts from various universities and institutions in several countries. PharmaCyte has expressed that all members of the Consortium are committed to developing a treatment for insulin-dependent diabetes using PharmaCyte Biotech’s Cell-in-a-Box(R) cellulose-based live-cell encapsulation technology combined with human non-pancreatic, insulin-producing cells (Melligen Cells). Since hitting March lows of $0.0990, shares of PMCB have risen by as much as 164% after April highs of $0.2615.

Recently PlasmaTech Biopharmaceuticals (NASDAQ: PTBI) has taken on an increased amount of attention in the market. Following the announcements Tuesday that billionaire investor George Soros purchased 1.16M shares of PTBI in late April, Shares of PlasmaTech rapidly rose in price from a Monday close of $2.86 to Highs on Tuesday of $7.77 representing a jump of 171.7% in the matter of a day. The Company has developed a robust product pipeline that includes two commercial stage products, MuGard(R) and ProctiGard(TM) as well as multiple pre-clinical follow-on products.

About Marijuanastocks.com

MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Contact Information:

marijuanastocks.com
800-539-4313
pr@marijuanastocks.com

SOURCE: MarijuanaStocks.com

ReleaseID: 428646